CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public offering of 5,405,406 shares of common stock at a price to the public of $37.00 per share for gross proceeds of $200.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 810,810 shares of common stock.

J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering. The offering is expected to close on or about September 25, 2017, subject to the satisfaction of customary closing conditions.

About Acceleron

Acceleron is a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases. Its pioneering research and protein engineering platform engages the target-rich TGF-beta superfamily and its remarkable ability to regulate cellular growth and repair.